Vanda Pharmaceuticals (VNDA)

$4.51 -0.09 (-1.96%)
Market Cap 271.81M
Revenue (ttm) 198.77M
Net Income (ttm) -18.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -9.51%
Debt to Equity Ratio 0.00
Volume 367,800
Avg Vol 477,022
Day's Range N/A - N/A
Shares Out 59.09M
Stochastic %K 10%
Beta 0.74
Analysts Sell
Price Target $12.67

Company Profile

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Ponvory for the treatment of psoriasis and ulcerative colitis. It...

Industry: Biotechnology
Sector: Healthcare
Phone: 202 734 3400
Fax: 202 296 1450
Address:
2200 Pennsylvania Avenue NW, Suite 300E, Washington, United States
Its_Only_Money_369
Its_Only_Money_369 Sep. 12 at 11:08 PM
$VNDA Anyone familiar with the takings claim $VNDA has filed agains the FDA. Just wondering what it is worth. I can see 2 billion in damages based on lost growth of revenue and market cap or 1 billion in loss of revenue and market cap. Not sure how damages wold be calculated if taking claim were successful.
1 · Reply
outlawinvestor1
outlawinvestor1 Sep. 11 at 10:15 PM
$VNDA i agree. the discussion was quite enlightening. a link to the audio is below. the one question that i came away with is why would a patient want to switch to bysanti from fanapt. it's clear why vanda wants them to switch, but not so clear what would motivate the patient to switch, given there are no real benefits of bysanti over fanapt for the patient. https://sqps.onstreamsecure.com/origin/enliven/players/EnlivenPlayer.html?customerId=22&eventId=45236323&checkCompany=1&checkEmail=1&checkName=1
1 · Reply
Texout
Texout Sep. 11 at 9:58 PM
$VNDA worth listening to the very recent cantor chat and replay. Olivia Brayer engaged with Kevin Moran, CFO of Vanda Pharmaceuticals. During this session, she inquired about the progress of Vanda’s interactions with the FDA concerning the Bysanti review, expected margins, and the potential impact of Medicaid post-launch. Additionally, she sought clarification on whether the FDA would require one or two Phase 3 studies for the Major Depressive Disorder (MDD) indication. Explicitly there is a discussion of market cap disconnect to the underlying financial health of vanda and the ongoing revenue developments and the trajectory.
0 · Reply
outlawinvestor1
outlawinvestor1 Sep. 11 at 8:29 PM
$VNDA just discovered this stock. i like that they are commercial stage with ok revenues, strong cash position, and no debt. however, revenues are decreasing and the most promising near term catalyst (bysanti fda approval) is unclear to me why patients would switch to it from fanpta. for those who understand this company well and have a balanced view, please let me know what i'm missing.
2 · Reply
Azbkr
Azbkr Sep. 11 at 3:35 PM
$VNDA Been accumulating $4 $5 & $7 3/26 calls for a few weeks now. They already have 3 approved products and two more approval dates in the next few months. No brainer!!!
0 · Reply
Texout
Texout Sep. 10 at 4:45 PM
$VNDA still mispriced by way more than 100% atm. Already own between 0,5% -1% of the company and will add.
2 · Reply
BioRich
BioRich Sep. 10 at 1:31 PM
$VNDA breakout coming? Think it's $VNDA time to shine!
1 · Reply
Estimize
Estimize Sep. 10 at 1:06 PM
Wall St is expecting -0.43 EPS for $VNDA Q3 [Reporting 10/29 BMO] http://www.estimize.com/intro/vnda?chart=historical&metric_name=eps&utm_c
0 · Reply
HorizonBull
HorizonBull Sep. 5 at 7:03 PM
$VNDA
0 · Reply
HFlier
HFlier Sep. 5 at 6:31 PM
$VNDA Maybe Monday we will get lucky and they will announce Polymeropoulos is stepping aside to let someone that knows how to increase shareholder value to take over. He should be personally liable for not accepting to the 100% premium buyout offer. He has done nothing to deliver on share price since then. Bullish on the company under new leadership.
1 · Reply
Latest News on VNDA
Vanda: Next Phase Of Fanapt Growth Might Be With Bysanti Advancement

Aug 29, 2025, 3:21 PM EDT - 14 days ago

Vanda: Next Phase Of Fanapt Growth Might Be With Bysanti Advancement

Vanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences

Aug 28, 2025, 5:23 PM EDT - 15 days ago

Vanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences

Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera

Aug 28, 2025, 7:00 AM EDT - 15 days ago

Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera

Vanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision to Uphold Approval of Two Generic Versions of Hetlioz®

Aug 21, 2025, 4:40 PM EDT - 22 days ago

Vanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision to Uphold Approval of Two Generic Versions of Hetlioz®

In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder

Aug 18, 2025, 7:00 AM EDT - 25 days ago

In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder

Vanda Pharmaceuticals Inc. (VNDA) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 4:45 PM EDT - 6 weeks ago

Vanda Pharmaceuticals Inc. (VNDA) Q2 2025 Earnings Call Transcript

Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results

Jul 31, 2025, 7:30 AM EDT - 6 weeks ago

Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results

Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025

Jul 23, 2025, 4:45 PM EDT - 7 weeks ago

Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025

Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S

Jun 10, 2025, 8:00 AM EDT - 3 months ago

Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S

Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting

May 27, 2025, 9:00 AM EDT - 3 months ago

Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting

Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025

May 16, 2025, 5:30 PM EDT - 4 months ago

Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025

Vanda Pharmaceuticals Inc. (VNDA) Q1 2025 Earnings Call Transcript

May 7, 2025, 7:55 PM EDT - 4 months ago

Vanda Pharmaceuticals Inc. (VNDA) Q1 2025 Earnings Call Transcript

Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results

May 7, 2025, 4:01 PM EDT - 4 months ago

Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results

Vanda Announces Bysanti™ NDA Filing; FDA Decision Expected in Early 2026

May 5, 2025, 8:00 AM EDT - 4 months ago

Vanda Announces Bysanti™ NDA Filing; FDA Decision Expected in Early 2026

Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025

May 2, 2025, 8:46 AM EDT - 4 months ago

Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025

FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA

Apr 23, 2025, 3:52 PM EDT - 5 months ago

FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA

Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting

Apr 7, 2025, 8:00 AM EDT - 5 months ago

Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting

Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia

Mar 31, 2025, 8:00 AM EDT - 5 months ago

Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia

Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S"

Feb 24, 2025, 7:00 AM EST - 7 months ago

Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S"

Vanda Pharmaceuticals, Inc. (VNDA) Q4 2024 Earnings Call Transcript

Feb 13, 2025, 10:29 PM EST - 7 months ago

Vanda Pharmaceuticals, Inc. (VNDA) Q4 2024 Earnings Call Transcript

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 13, 2025, 4:01 PM EST - 7 months ago

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

Feb 5, 2025, 4:30 PM EST - 7 months ago

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis

Jan 27, 2025, 7:00 AM EST - 8 months ago

Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis

Vanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review

Jan 8, 2025, 4:17 PM EST - 8 months ago

Vanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review

Vanda Pharmaceuticals: Net-Net Status Presents A Trading Opportunity

Dec 20, 2024, 1:26 PM EST - 9 months ago

Vanda Pharmaceuticals: Net-Net Status Presents A Trading Opportunity

Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera

Dec 20, 2024, 9:13 AM EST - 9 months ago

Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera

Glancy Prongay & Murray LLP Announces Investigation of Vanda Pharmaceuticals Inc.

Dec 16, 2024, 9:29 PM EST - 9 months ago

Glancy Prongay & Murray LLP Announces Investigation of Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Announces Participation at November 2024 Investor Conferences

Nov 12, 2024, 4:58 PM EST - 10 months ago

Vanda Pharmaceuticals Announces Participation at November 2024 Investor Conferences

Vanda Pharmaceuticals Inc. (VNDA) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 8:20 PM EST - 11 months ago

Vanda Pharmaceuticals Inc. (VNDA) Q3 2024 Earnings Call Transcript

Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results

Nov 6, 2024, 4:02 PM EST - 11 months ago

Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results

Over 200% Stock Upside - Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst

Nov 1, 2024, 2:05 PM EDT - 11 months ago

Over 200% Stock Upside - Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst

Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024

Oct 30, 2024, 4:30 PM EDT - 11 months ago

Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024

Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd.

Oct 14, 2024, 10:56 AM EDT - 11 months ago

Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd.

Cycle Pharma maintains takeover offer for Vanda Pharmaceuticals

Oct 14, 2024, 10:37 AM EDT - 11 months ago

Cycle Pharma maintains takeover offer for Vanda Pharmaceuticals

Cycle Pharmaceuticals Reaffirms All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share

Oct 14, 2024, 8:19 AM EDT - 11 months ago

Cycle Pharmaceuticals Reaffirms All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share

Vanda Pharmaceuticals decries FDA's rejection of stomach paralysis drug as unjust

Sep 19, 2024, 3:17 PM EDT - 1 year ago

Vanda Pharmaceuticals decries FDA's rejection of stomach paralysis drug as unjust

FDA Strikes Off Vanda Pharmaceuticals' Tradipitant For Stomach Paralysis, Asks For Additional Studies

Sep 19, 2024, 10:33 AM EDT - 1 year ago

FDA Strikes Off Vanda Pharmaceuticals' Tradipitant For Stomach Paralysis, Asks For Additional Studies

U.S. FDA declines to approve Vanda's stomach paralysis drug

Sep 19, 2024, 7:57 AM EDT - 1 year ago

U.S. FDA declines to approve Vanda's stomach paralysis drug

FDA Declines to Approve Vanda's Marketing Application for Tradipitant in Gastroparesis

Sep 19, 2024, 7:00 AM EDT - 1 year ago

FDA Declines to Approve Vanda's Marketing Application for Tradipitant in Gastroparesis

Vanda Pharmaceuticals Announces Participation in the 2024 Cantor Global Healthcare Conference

Sep 11, 2024, 5:00 PM EDT - 1 year ago

Vanda Pharmaceuticals Announces Participation in the 2024 Cantor Global Healthcare Conference

Its_Only_Money_369
Its_Only_Money_369 Sep. 12 at 11:08 PM
$VNDA Anyone familiar with the takings claim $VNDA has filed agains the FDA. Just wondering what it is worth. I can see 2 billion in damages based on lost growth of revenue and market cap or 1 billion in loss of revenue and market cap. Not sure how damages wold be calculated if taking claim were successful.
1 · Reply
outlawinvestor1
outlawinvestor1 Sep. 11 at 10:15 PM
$VNDA i agree. the discussion was quite enlightening. a link to the audio is below. the one question that i came away with is why would a patient want to switch to bysanti from fanapt. it's clear why vanda wants them to switch, but not so clear what would motivate the patient to switch, given there are no real benefits of bysanti over fanapt for the patient. https://sqps.onstreamsecure.com/origin/enliven/players/EnlivenPlayer.html?customerId=22&eventId=45236323&checkCompany=1&checkEmail=1&checkName=1
1 · Reply
Texout
Texout Sep. 11 at 9:58 PM
$VNDA worth listening to the very recent cantor chat and replay. Olivia Brayer engaged with Kevin Moran, CFO of Vanda Pharmaceuticals. During this session, she inquired about the progress of Vanda’s interactions with the FDA concerning the Bysanti review, expected margins, and the potential impact of Medicaid post-launch. Additionally, she sought clarification on whether the FDA would require one or two Phase 3 studies for the Major Depressive Disorder (MDD) indication. Explicitly there is a discussion of market cap disconnect to the underlying financial health of vanda and the ongoing revenue developments and the trajectory.
0 · Reply
outlawinvestor1
outlawinvestor1 Sep. 11 at 8:29 PM
$VNDA just discovered this stock. i like that they are commercial stage with ok revenues, strong cash position, and no debt. however, revenues are decreasing and the most promising near term catalyst (bysanti fda approval) is unclear to me why patients would switch to it from fanpta. for those who understand this company well and have a balanced view, please let me know what i'm missing.
2 · Reply
Azbkr
Azbkr Sep. 11 at 3:35 PM
$VNDA Been accumulating $4 $5 & $7 3/26 calls for a few weeks now. They already have 3 approved products and two more approval dates in the next few months. No brainer!!!
0 · Reply
Texout
Texout Sep. 10 at 4:45 PM
$VNDA still mispriced by way more than 100% atm. Already own between 0,5% -1% of the company and will add.
2 · Reply
BioRich
BioRich Sep. 10 at 1:31 PM
$VNDA breakout coming? Think it's $VNDA time to shine!
1 · Reply
Estimize
Estimize Sep. 10 at 1:06 PM
Wall St is expecting -0.43 EPS for $VNDA Q3 [Reporting 10/29 BMO] http://www.estimize.com/intro/vnda?chart=historical&metric_name=eps&utm_c
0 · Reply
HorizonBull
HorizonBull Sep. 5 at 7:03 PM
$VNDA
0 · Reply
HFlier
HFlier Sep. 5 at 6:31 PM
$VNDA Maybe Monday we will get lucky and they will announce Polymeropoulos is stepping aside to let someone that knows how to increase shareholder value to take over. He should be personally liable for not accepting to the 100% premium buyout offer. He has done nothing to deliver on share price since then. Bullish on the company under new leadership.
1 · Reply
MarkM
MarkM Sep. 5 at 3:39 PM
$VNDA Price is finding support at the weekly 50 SMA. That's good. Might be ready to exit the nearly year long consolidation box with a multi week move up: $5 and then $6. BO rumor catalysts could get us there in a flash. In the absence of this, still looking for organic growth towards these targets over the next 6 months.
0 · Reply
HFlier
HFlier Sep. 4 at 8:23 PM
$VNDA Kill the commercials and do a big stock buyback.
0 · Reply
HFlier
HFlier Sep. 4 at 4:41 PM
$VNDA Good grief.
0 · Reply
HorizonBull
HorizonBull Sep. 4 at 3:30 PM
$VNDA added 2k 4.60.
0 · Reply
HorizonBull
HorizonBull Sep. 4 at 1:41 AM
$VNDA
0 · Reply
Kascnef82
Kascnef82 Sep. 3 at 7:52 PM
$VNDA I’ve seen ads during baseball ⚾️
0 · Reply
onemillion2012
onemillion2012 Sep. 3 at 2:39 PM
$BCAB she is moving. Get in now at under 50 cent. Come friends from $VNDA $ASMB It's a double or triple in 2 monts
0 · Reply
Texout
Texout Sep. 3 at 2:12 PM
$VNDA adding
0 · Reply
HFlier
HFlier Sep. 2 at 6:59 PM
$VNDA Big tails on the candles on the daily chart. Someone wants out every push up. Still sucking.
0 · Reply
Trendrebel
Trendrebel Sep. 1 at 7:57 AM
$VNDA Weekly update on the chart. I moved the trendline of the last shoulder, to a supportive TL, because the short term trend is up, and we still trade above MA50. Nothing has really changed last week. * The last red candle was a test of Fibo 63,8%, and got rejected. * Trend is still up, and the possibilities are bullish with a target to test 5.17 ( neckline of inversed SHS ). * 5.03 is the Fibo50%, which is a test of strength in the trend. * Volume is weak, which might blur the signals, though.
0 · Reply
HFlier
HFlier Aug. 31 at 7:27 PM
$VNDA Chart is finally starting to look ok.
0 · Reply
HFlier
HFlier Aug. 29 at 11:13 AM
$VNDA Needs to break $4.82 hard within the next few days (preferably today) or we will be headed for a lower-low on the weekly. Would be nice if this finally really started to move. Volume is low because people just got tired of nothing.
0 · Reply